News | May 12, 2022
Suven Pharmaceuticals - CDMO core growth intact; formulations to pick up
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
Casper Pharma is a Hyderabad based SEZ company engaged in the formulations business. Post-purchase of shares, the target entity would become a wholly-owned subsidiary of SPL
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
Postal ballot also clears remuneration proposal and new ESOP 2026 scheme, strengthening the company’s leadership and talent retention strategy
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
